Studies immune markers in tumor samples from people with advanced lung cancer
Observes immune and tumor markers in adults with advanced lung cancer receiving immunochemotherapy.
Plain-language title generated from the registry record
Registry title: Immune-Marker Platform for Patients With Advanced Lung Cancer
Key facts
- Where
- Cologne and Dresden, GermanySee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced non-small cell lung cancer who have no targetable gene change and low PD-L1. They give tumor samples during immunochemotherapy.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced non-small cell lung cancer (NSCLC) with no curative treatment option. Cohort A: not yet treated. Cohort B: cancer has progressed after first-line immune(chemo)therapy.
- Earlier treatment
- Cohort A: no previous treatment for this cancer, and immune(chemo)therapy is planned. Cohort B: progression after first-line immune(chemo)therapy.
- Biomarker or test result
- No targetable driver mutation in ALK, EGFR, BRAF, HER2, MET, NTRK, RET, ROS1. PD-L1 on tumor cells (TPS) below 50%. Consent to join the national Network for Genomic Medicine in Lung Cancer (nNGM).
Main reasons for not taking part
- A condition that makes an extra biopsy an unjustified risk in the investigator's view
- Cannot understand the purpose and possible consequences of the trial
- Substance abuse, or medical, psychological or social conditions that may interfere with taking part
Read by machine on 12 November 2026.
Where in Germany
- Universitätsklinikum Köln, Centrum für Integrierte Onkologie (CIO) KölnCologne, GermanyContact: Jürgen Wolf, Prof. Dr.No longer taking part
- Universitätsklinikum Carl Gustav CarusDresden, GermanyContact: Martin Wermke, Prof. Dr.No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Technische Universität Dresden
- Trial code
- NCT07150598
- Record updated
- 8 September 2025
- Original description
The goal of this observational study is to better understand how the immune system and certain tumor markers are linked to treatment response in patients with advanced non-small cell lung cancer (NSCLC) who receive immunochemotherapy.Read full original descriptionShow less
Immune-Marker Platform for Patients With Advanced Lung Cancer
The goal of this observational study is to better understand how the immune system and certain tumor markers are linked to treatment response in patients with advanced non-small cell lung cancer (NSCLC) who receive immunochemotherapy.
The investigators aim to answer the following questions:
* Can the investigators successfully analyze immune markers and gene activity from small tumor samples (biopsies)? * Are these markers connected to how well patients respond to immunochemotherapy and how their disease progresses?
What will participants do?
* Provide tumor tissue samples (biopsies) at key points: before treatment, about 6 weeks after starting immunochemotherapy, and if the cancer grows or treatment changes. * Allow their tumor samples to be analyzed in the lab using advanced techniques to measure immune and genetic markers. * Share clinical information (such as treatment response and disease progression) so investigators can study how it relates to these markers.
This study does not test a new drug or treatment.
Inclusion: For all:; Written informed consent of the patient; Consent of participation in the national Network for Genomic Medicine in Lung Cancer (nNGM); Advanced lung cancer with non-curative treatment option (NSCLC); No targetable driver mutation detected, defined as no targetable drive mutation in ALK, EGFR, BRAF, HER2, MET, NTRK, RET, ROS1; PD-L1 expression on tumor cells (TPS < 50%); Cohort A:; Previously untreated NSCLC without curative treatment options; Sufficient pre-treatment tumor material available for the planned analyses or consenting and able to undergo additional pretreatment biopsy; Scheduled to undergo immune(chemo)therapy; Willing and able to undergo re-biopsy 6 weeks after start of immune(chemo)therapy; Cohort B:; Any line of progression after firstline immune(chemo)therapy; Sufficient tumor material obtained after progression on most recent line of treatment available or willing and able to undergo re-biopsy prior to next line treatment.
Exclusion: Any condition representing an unjustified risk for obtaining an additional biopsy sample (if needed) in the view of the investigator; Substance abuse, medical, psychological or social conditions that may interfere with the subject's cooperation with the requirements of the trial or evaluation of the study results; Incapability of understanding the purpose and possible consequences of the trial.